Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Lymphoma, Large B-Cell, Diffuse 4Lymphoma, Follicular 4Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma 2Breast Neoplasms 2Advanced Malignancies 2Unresectable or Metastatic Solid Tumors 1Triple Negative Breast Neoplasms 1Solid Tumors 1Recurrence 1Pancreatic Neoplasms 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, B-Cell 1Lung Neoplasms 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 47Nivolumab 34Sunitinib 18Cyclophosphamide 18Everolimus 17Ipilimumab 15cabozantinib 14pazopanib 13Bevacizumab 13fludarabine 12atezolizumab 11temsirolimus 10Magnetic Resonance Spectroscopy 10Sorafenib 9aldesleukin 8Specimen Handling 8Paclitaxel 8Sirolimus 7CTLA-4 Antigen 7Axitinib 7belzutifan 6Radiosurgery 6Oxaliplatin 6Interleukin-2 6Fluorouracil 6spartalizumab 5avelumab 5Leucovorin 5Irinotecan 5Docetaxel 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Carcinoma, Renal Cell × parsaclisib × Clear all
NCT02646748 2022-03-31

Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors

Incyte Corporation

Phase 1 Completed
159 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡